A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ji, Jun Ho | - |
dc.contributor.author | Yun, Tak | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Park, Ji Chan | - |
dc.contributor.author | Cho, In Sung | - |
dc.contributor.author | Sohn, Chang Hak | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Jang, Joung Soon | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Hwang, Deok Won | - |
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.date.available | 2019-05-29T05:35:18Z | - |
dc.date.issued | 2012-11 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.issn | 1879-0852 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20050 | - |
dc.description.abstract | Background: The purpose of this phase II study was to determine the efficacy and toxicity of cisplatin and weekly docetaxel combination chemotherapy as a first-line treatment in patients with recurrent or metastatic nasopharyngeal cancer. Patients and Methods: Recurrent or metastatic nasopharyngeal cancer patients were enrolled and received a combination of weekly docetaxel (35 mg/m(2) on Day1 and Day8) and cisplatin (70 mg/m(2) D1) every 21 days, for up to a maximum of 6 cycles. The primary endpoint was objective response rate, and the secondary endpoints included toxicity of combination chemotherapy, progression-free survival, overall survival and 1-year survival rate. Results: In total, 47 patients were enrolled and analysed, and 46 patients (97.9%) completed the planned protocol. In an intent-to-treat analysis, 6 patients (12.8%) achieved complete response (CR) and 27 patients (57.4%) showed partial response (PR), with an objective response rate of 70.2%. The median progression-free survival and overall survival were 9.6 months (95% C.I. 5.7-13.5 months) and 28.5 months (95% C.I. 16.9-40.1 months), respectively, and the 1-year survival rate was 89.9%. The common grade 3 adverse events were stomatitis (1.2%), neutropenia (0.8%), anaemia (0.8%), infection (0.8%) and diarrhoea (0.8%). Grade 4 adverse events were not observed in this study. Conclusions: The combination chemotherapy of cisplatin and weekly docetaxel is highly effective and shows favourable toxicity as a first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal cancer. (C) 2012 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ejca.2012.06.009 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.48, no.17, pp 3198 - 3204 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000310569400009 | - |
dc.identifier.scopusid | 2-s2.0-84868213013 | - |
dc.citation.endPage | 3204 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 3198 | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 48 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Nasopharyngeal cancer | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Weekly docetaxel | - |
dc.subject.keywordPlus | PLATINUM-BASED CHEMOTHERAPY | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | CONCURRENT CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | PLUS CISPLATIN | - |
dc.subject.keywordPlus | ASIAN PATIENTS | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.